Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.

J Diabetes Investig · 2020 · PMC7232283 · PMID 31721467

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

nearly significantP = 0.052so close (0.05 < p ≤ 0.1)

Myostatin levels were significantly decreased ( P = 0.010), and irisin levels showed a nearly significant reduction ( P = 0.052) in the dapagliflozin group compared with the control group, whereas FGF21 levels did not change significantly from baseline to the end of the intervention in both the dapagliflozin ( P = 0.673) and the control ( P = 0.823) groups.

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.